Effect of interferon-α and thymopentin on the mRNA expression of APOBEC3A and APOBEC3B in HepG2.2.15 cells
10.3969/j.issn.1001-5256.2020.01.017
- VernacularTitle:干扰素α和胸腺五肽协同干预对HepG2
- Author:
Fang XIONG
1
;
Yao GAO
;
Yanpin MA
Author Information
1. Department of Hepatopathy and Cancer Biotherapy, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
- Publication Type:Research Article
- Keywords:
interferon-alpha;
thymopentin;
APOBEC deaminases
- From:
Journal of Clinical Hepatology
2020;36(1):76-79
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effect of synergistic intervention of interferonα (IFNα) and thymopentin (TP5) on the mRNA expression of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A) and apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B (APOBEC3B) in HepG2.2.15 cells. MethodsHepG2.2.15 cells were divided into blank control group, IFNα treatment group, TP5 treatment group, and IFNα+TP5 treatment group, and at 12, 24, 48, and 72 hours of treatment, quantitative real-time PCR was used to measure the mRNA expression of APOBEC3A and APOBEC3B in HepG2.2.15 cells. An analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. ResultsCompared with the blank control group, the IFNα treatment group and the IFNα+TP5 treatment group had a significant increase in the mRNA expression of APOBEC3A at 12, 24, 48, and 72 hours of treatment (all P＜0001). Compared with the IFNα treatment group, the IFNα+TP5 treatment group had a significant increase in the mRNA expression of APOBEC3A at these four time points (all P＜0.001). TP5 treatment had no significant influence on the mRNA expression of APOBEC3A at each time point (all P＞0.05). There was no significant difference in the mRNA expression of APOBEC3B between the blank control group and the treatment groups (all P＞0.05). ConclusionIFNα combined with TP5 can significantly upregulate the mRNA expression of APOBEC3A in HepG2.2.15 cells.
